<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355368</url>
  </required_header>
  <id_info>
    <org_study_id>EK 145/05</org_study_id>
    <nct_id>NCT00355368</nct_id>
  </id_info>
  <brief_title>Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care</brief_title>
  <official_title>Phase 4 Study of Succinylcholine Versus Rocuronium as Neuromuscular Blocking Agent for Emergency Intubation in Intensive Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emergency intubation of patients in intensive care is a high-risk endeavour. For many
      decades, succinylcholine has been the neuromuscular blocking agent of choice. However,
      succinylcholine may have life-threatening side effects and is contraindicated in a variety of
      diseases relevant in intensive care. The nondepolarizing agent rocuronium has been propagated
      as alternative for succinylcholine. Though a recent meta-analysis found no difference in
      intubating conditions between succinylcholine and rocuronium in elective cases, there are no
      data in emergent cases in intensive care. The aim of the present study is to compare
      succinylcholine and rocuronium with regard to 1) quality of intubating conditions, 2) length
      of the intubating sequence, 3) failed intubating attempts, 4) hemodynamic sequelae of
      intubation, and 5) desaturations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: to compare succinylcholine and rocuronium with regard to 1) quality of intubating
      conditions, 2) length of the intubating sequence, 3) failed intubating attempts, 4)
      hemodynamic sequelae of intubation, and 5) desaturations.

      Design: prospective, randomized, single-blind study. Setting: Intensive care units of an
      University Hospital. Patients: adult patients in intensive care requiring emergency
      intubation. Randomization: 1:1 randomization to either succinylcholine (1mg/kg) or rocuronium
      (0.6 mg/kg).

      Data: 1) assessment of the quality of intubating conditions by means of a score, 2) length of
      the intubating sequence defined as time between injection of neuromuscular blocking agent and
      first end-tidal CO2 on the monitor, 3) number of failed intubating attempts, 4) hemodynamic
      sequelae of intubation, defined as events requiring injection of vasoactive drugs, and 5)
      desaturations, defined as saturation below 90% and/or any decrease in saturation of 5% or
      more.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Exhibiting Desaturation &gt;5%</measure>
    <time_frame>at any time between the start of the intubation sequence and 2min after the completion of intubation</time_frame>
    <description>decrease of &gt;5% in oxygen saturation measured continuously using pulse oxymetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic Sequelae of Intubation</measure>
    <time_frame>between start of induction sequence and 5 min after completion of intubation</time_frame>
    <description>any new haemodynamic alteration requiring immediate intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Completion of Intubation</measure>
    <time_frame>time interval between the injection of the induction agent and the first appearance of endtidal CO2</time_frame>
    <description>time interval between the injection of the induction agent and the first appearance of endtidal CO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Intubation Conditions Using a Validated Score: Viby-Mogensen et al. Good Clinical Research Practice (GCRP) in Pharmacodynamic Studies of Neuromuscular Blocking Agents. Acta Anaesthesiol Scand 1996;40:59-74.</measure>
    <time_frame>during laryngoscopy and the first minute after completion of intubation</time_frame>
    <description>The factors laryngoscopy, vocal cords, and response to intubation are individually rated with a score from 1 (bad intubation conditions)to 3 (excellent intubation conditions)and the resulting three scores are summed up. The maximum score is thus 9 while the minimum score is 3.
Units: measure on a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Failed First Intubation Attempts</measure>
    <time_frame>within the first 90 sec following the start of induction</time_frame>
    <description>defined as either uncompleted intubation attempt within 90 sec or starting a second intubation attempt</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Intubation</condition>
  <arm_group>
    <arm_group_label>Succinylcholine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Succinylcholine</intervention_name>
    <description>1mg/kg iv</description>
    <arm_group_label>Succinylcholine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>0.6mg/kg iv</description>
    <arm_group_label>Rocuronium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  indication for emergency intubation in intensive care

          -  availability of qualified study physician

        Exclusion Criteria:

          -  contraindication against succinylcholine or rocuronium

          -  indication for awake fibreoptic intubation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Siegemund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgical Intensive Care, University of Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan C Marsch, MD, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medical Intensive Care, University of Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medical Intensive Care; University of Basel</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Sluga M, Ummenhofer W, Studer W, Siegemund M, Marsch SC. Rocuronium versus succinylcholine for rapid sequence induction of anesthesia and endotracheal intubation: a prospective, randomized trial in emergent cases. Anesth Analg. 2005 Nov;101(5):1356-61.</citation>
    <PMID>16243994</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2006</study_first_submitted>
  <study_first_submitted_qc>July 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2006</study_first_posted>
  <results_first_submitted>August 8, 2011</results_first_submitted>
  <results_first_submitted_qc>November 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2011</results_first_posted>
  <last_update_submitted>November 10, 2011</last_update_submitted>
  <last_update_submitted_qc>November 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Stephan Marsch</investigator_full_name>
    <investigator_title>Professor and Chairman of Medical ICU</investigator_title>
  </responsible_party>
  <keyword>intubation</keyword>
  <keyword>intensive care</keyword>
  <keyword>neuromuscular depolarizing agents</keyword>
  <keyword>neuromuscular nondepolarizing agents</keyword>
  <keyword>neuromuscular blocking agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Neuromuscular Nondepolarizing Agents</mesh_term>
    <mesh_term>Succinylcholine</mesh_term>
    <mesh_term>Neuromuscular Blocking Agents</mesh_term>
    <mesh_term>Neuromuscular Depolarizing Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Succinylcholine</title>
          <description>1mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Rocuronium</title>
          <description>0.6mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>cardiac arrest prior to intubation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Succinylcholine</title>
          <description>1mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Rocuronium</title>
          <description>0.6mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="210"/>
            <count group_id="B2" value="210"/>
            <count group_id="B3" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="16"/>
                    <measurement group_id="B2" value="63" spread="14"/>
                    <measurement group_id="B3" value="61" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Exhibiting Desaturation &gt;5%</title>
        <description>decrease of &gt;5% in oxygen saturation measured continuously using pulse oxymetry</description>
        <time_frame>at any time between the start of the intubation sequence and 2min after the completion of intubation</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Succinylcholine</title>
          </group>
          <group group_id="O2">
            <title>Rocuronium</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Exhibiting Desaturation &gt;5%</title>
          <description>decrease of &gt;5% in oxygen saturation measured continuously using pulse oxymetry</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haemodynamic Sequelae of Intubation</title>
        <description>any new haemodynamic alteration requiring immediate intervention</description>
        <time_frame>between start of induction sequence and 5 min after completion of intubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Completion of Intubation</title>
        <description>time interval between the injection of the induction agent and the first appearance of endtidal CO2</description>
        <time_frame>time interval between the injection of the induction agent and the first appearance of endtidal CO2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Succinylcholine</title>
          </group>
          <group group_id="O2">
            <title>Rocuronium</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Completion of Intubation</title>
          <description>time interval between the injection of the induction agent and the first appearance of endtidal CO2</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" spread="38"/>
                    <measurement group_id="O2" value="95" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Intubation Conditions Using a Validated Score: Viby-Mogensen et al. Good Clinical Research Practice (GCRP) in Pharmacodynamic Studies of Neuromuscular Blocking Agents. Acta Anaesthesiol Scand 1996;40:59-74.</title>
        <description>The factors laryngoscopy, vocal cords, and response to intubation are individually rated with a score from 1 (bad intubation conditions)to 3 (excellent intubation conditions)and the resulting three scores are summed up. The maximum score is thus 9 while the minimum score is 3.
Units: measure on a scale</description>
        <time_frame>during laryngoscopy and the first minute after completion of intubation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Succinylcholine</title>
          </group>
          <group group_id="O2">
            <title>Rocuronium</title>
          </group>
        </group_list>
        <measure>
          <title>Quality of Intubation Conditions Using a Validated Score: Viby-Mogensen et al. Good Clinical Research Practice (GCRP) in Pharmacodynamic Studies of Neuromuscular Blocking Agents. Acta Anaesthesiol Scand 1996;40:59-74.</title>
          <description>The factors laryngoscopy, vocal cords, and response to intubation are individually rated with a score from 1 (bad intubation conditions)to 3 (excellent intubation conditions)and the resulting three scores are summed up. The maximum score is thus 9 while the minimum score is 3.
Units: measure on a scale</description>
          <units>score points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="0.8"/>
                    <measurement group_id="O2" value="8.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Failed First Intubation Attempts</title>
        <description>defined as either uncompleted intubation attempt within 90 sec or starting a second intubation attempt</description>
        <time_frame>within the first 90 sec following the start of induction</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Succinylcholine</title>
          </group>
          <group group_id="O2">
            <title>Rocuronium</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Failed First Intubation Attempts</title>
          <description>defined as either uncompleted intubation attempt within 90 sec or starting a second intubation attempt</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Succinylcholine</title>
          <description>1mg/kg</description>
        </group>
        <group group_id="E2">
          <title>Rocuronium</title>
          <description>0.6mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephan Marsch</name_or_title>
      <organization>Medical Intensive care unit, University Hospital Basel</organization>
      <phone>+ 41 61 265 2525</phone>
      <email>smarsch@uhbs.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

